This case illustrates the importance taking into account timing of imaging with respect to treatment (pseudoprogression typically occurs in the first three months following completion of chemoradiotherapy (which usually lasts ~3 months)). It is also important to know MGMT status, as methylation significantly increases the likelihood of pseudoprogression occurring. 

The diagnosis of GBM is actually not entirely established in this case as the IDH wild-type status has only been inferred with a negative IDH1 R132H immunohistochemistry. Although it is highly likely to reflect true IDH wild-type status, it is possible that this is a non-R132H mutation or an IDH2 mutation. In such cases, when the patient is young IDH sequencing is recommended to prove that no IDH mutation is present. If an IDH mutation was found, then 1p19q codeletion status would also need to be established (intact ATRX suggests 1p19q codeletion). This is important from a classification and prognosis point of view as if an IDH mutation was found and 1p19q was co-deleted then this tumor would actually represent an anaplastic oligodendroglioma and not at glioblastoma.